Liposomal irinotecan pancreatic cancer：Liposomal Irinotecan in the Treatment of Refractory ...

Clinical outcomes of liposomal irinotecan in advanced ...

https://www.ncbi.nlm.nih.gov

The efficacy of combination chemotherapy beyond the first-line setting remains modest in patients with advanced pancreatic adenocarcinoma (PAC).

First

https://dailynews.ascopubs.org

Key Points: ... Liposomal irinotecan given with 5-fluorouracil/leucovorin is currently approved for the treatment of patients with metastatic ...

Liposomal irinotecan (Onivyde)

https://pubmed.ncbi.nlm.nih.go

However, irinotecan has not been successfully introduced as a second-line treatment for pancreatic cancer and few randomized clinical studies have evaluated its ...

Liposomal Irinotecan Shows a Larger Therapeutic Index ...

https://www.ncbi.nlm.nih.gov

Irinotecan (CPT-11) is a chemotherapeutic agent used to treat pancreatic cancer. Both irinotecan and its active metabolite SN-38 (converted by ...

Liposomal Irinotecan

https://www.ncbi.nlm.nih.gov

Liposomal irinotecan, in combination with 5-FU/LV, is the first agent to be specifically approved for use in patients with mPDAC who have ...

NAPOLI

https://www.ejcancer.com

Final analysis of NAPOLI-1 trial of liposomal irinotecan confirmed primary analysis. •. Longer overall survival in metastatic pancreatic cancer ...

ONIVYDE® (irinotecan liposome injection)

https://www.onivyde.com

Prior irinotecan exposure does not preclude benefit to ...

https://www.ncbi.nlm.nih.gov

Liposomal irinotecan + 5‐FU/LV in metastatic pancreatic cancer: subgroup analyses of patient, tumor, and previous treatment characteristics ...

Subgroup analysis of the NAPOLI

https://pubmed.ncbi.nlm.nih.go

The global, randomized NAPOLI-1 phase 3 trial reported a survival benefit with liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin ...